Medicated eye drops used to offset pressure spikes inside the eye have no effect on the pressure caused by intravitreal injections, a new study found. Reuters Health Information
Category: Retina
Interim guidance for management of retinal vein occlusion 2010
The document aims to provide updated recommendations on the management of retinal vein occlusion (RVO) in the light of recent developments in both diagnostic tools and treatment options that supersede those in the previous RVO guidelines. It has also r…
Persistent Flashes After Posterior Vitreous Detachment (PVD)
It is not uncommon for the symptoms of flashes to persist after a posterior vitreous detachment, or PVD. Flashes and floaters, common symptoms of a PVD, may also be warning signs of a possible retinal tear. Retinal tears can cause…
Stem Cells Get FDA Nod for Stargardt’s Disease
Advanced Cell Technology, Inc. gets FDA approval to use stem cells as a possible treatment for Stargardt’s disease, a inherited juvenile type of macular degeneration.
Avastin/Lucentis Update 44: United Kingdom Closer to Allowing Avastin for AMD
While the U.S. comes closer to showing the equivalency of Avastin to Lucentis for treating the wet form of age-related macular degeneration, when the CATT Study (Comparisons of Age-Related Macular Degeneration Treatments Trials) results become public, …
Omega 3 Rich Foods Protect Seniors From Age-Related Macular Degeneration (AMD)
Seniors whose diets are rich in omega 3 fatty acids have a significantly lower risk of developing AMD (age-related macular degeneration) compared to other people of the same age, scientists revealed in the journal Ophthalmology. Good sources of Omega 3…
Can Omega-3 Fatty Acids in Fish Prevent Age-Related Macular Degeneration?
The December 2010 issue of Ophthalmology reports on a study of 2520 residents of Salisbury, Maryland, aged 65 to 84 years to determine the relationship between fish and shellfish consumption and age-related macular degeneration (AMD). Full Story →
Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: 1-year Outcomes of a Prospective, Double-masked Randomised Clinical Trial
This study compares two drugs in the treatment of age-related macular degeneration. Eye
Accumulated Doses of Irradiation to the Lens May be Cataractogenic
Irradiation toxic effects of intra-arterial chemotherapy
may be cataractogenic and possibly carcinogenic, especially
in irradiation-sensitive patients with retinoblastoma,
according to a study published in the Archives of
Ophthalmology.1
The prospectiv…
FAME: 24-month Readout Shows Steady Improvement
Vision continued to significantly improve at 2 years with
the fluocinolone acetonide intravitreal insert (Iluvien,
Alimera Sciences), according to Baruch D. Kuppermann,
MD, PhD, who presented the 24-month readout of the
FAME trial at the American Acade…
Carl Zeiss Introduces Multispot Photocoagulation Laser
Carl Zeiss Meditec, Inc. (Dublin, CA), introduced the
Visulas 532s Vite photocoagulator at the AAO in Chicago.
The device recently received marketing clearance from
the FDA. According to the company, the Visulas 532s Vite
photocoagulator features varia…
Ranibizumab Improved Visual Outcomes in DME
Patients with DME achieved better long-term visual
outcomes when treated with ranibizumab (Lucentis,
Genentech) and focal/grid laser combination therapy
than with ranibizumab or laser alone, according to the
results of the phase 2 READ-2 study publishe…
VEGF Trap-Eye Noninferior to Ranibizumab in Two Phase 3 Trials
In patients with wet age-related macular degeneration
(AMD), all regimens of aflibercept (VEGF Trap-
Eye, Regeneron), including aflibercept dosed every
2 months, achieved the primary endpoint compared
with ranibizumab (Lucentis, Genentech) dosed every
…
Pegaptanib Maintained Vision Gains at 2 Years
Pegaptanib sodium injection (Macugen, Eyetech, Inc.)
significantly improved vision in patients with DME and
maintained and expanded vision gains in patients over a
2-year period, according to phase 3 data presented by
Marla B. Sultan, MD, MBA, at the A…
Eyetech Awarded Grant for Extended-Release Formulation of Macugen
Eyetech Inc. (Palm Beach Gardens, FL) has been awarded
a $245,000 grant to support the development of an
extended-release formulation of pegaptanib sodium
injection (Macugen) using microparticles technology,
according to a company news release.
At the …
FDA Permits Stem Cell Clinical Trial for Stargardt to Begin
Advanced Cell Technology, Inc. (Santa Monica, CA), has
received clearance from the FDA to conduct a phase 2/3
clinical trial using retinal pigment epithelium (RPE) cells
derived from human embryonic stem cells to treat patients
with Stargardt macular d…
VisionCare’s AMD Telescope Wins Award
The Implantable Miniature Telescope (IMT; VisionCare
Ophthalmic Technologies, Inc., Saratoga, CA) was recently named “Best of What’s New” 2010 by Popular
Science magazine. Created by Isaac Lipshitz, MD, the
miniature device is designed to improve…
Canon’s CR-2 Digital Non- Mydriatic Retinal Camera Receives FDA Clearance
The Canon CR-2 Digital Non-Mydriatic Retinal Camera
(Canon USA, Inc., Lake Success, NY) has received 510(k)
clearance from the FDA. The CR-2 integrates the latest in
Canon’s retinal imaging technology and enhancements in
a compact frame and is the li…
Single Injection of Bevacizumab Effective in Eyes With Myopic Choroidal Neovascularization
One intravitreal injection of bevacizumab (Avastin,
Genentech) seems to be an effective therapeutic
approach to treat choroidal neovascularization in
highly myopic eyes, according to a study in Retina.1
José M. Ruiz-Moreno, MD, PhD, of the Instituto
O…
EyeGate to Develop Corticosteroid Solution for Retinal Disorders
EyeGate Pharma (Waltham, MA) announced that it
has received four federal grants totaling nearly $1 million
for programs that focus on the continued clinical development
of EGP-437, a corticosteroid solution administered by the EyeGate II delivery syste…